🕒 Last update: loading…

Stock Pediatrix Medical Group, Inc. MD

Pediatrix Medical Group, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -15.79%

Price change 2019 → 2020: -11.69%

Price change 2020 → 2021: 10.88%

Price change 2021 → 2022: -45.39%

Price change 2022 → 2023: -37.42%

Price change 2023 → 2024: 41.08%

Price change 2024 → 2025: 63.03%

Price change 2025 → 2026: 20.43%

Price change 2026 (year to date): 21.00%

Financial growth

Revenue CAGR (8 years): -8.80%

Earnings CAGR (8 years): -6.69%

Growth status: weak or negative trend (<1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 0.76

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 11.59

P/E < 25.0 (maximum threshold).

Correction (6 months)

Current correction: 5.95% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Pediatrix Medical Group, Inc.14.00.76+2.1 %🔒
Addus HomeCare Corporation18.60.19+11.7 %★ 4/5
Vir Biotechnology, Inc.–0.24+115.2 %–
Fleury S.A.16.31.05+16.2 %–
Emeis–6.11+11.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Pediatrix Medical Group, Inc. over the latest fiscal years.

Revenue
1.9 bn USD
fiscal year 2025
Net income
165 m USD
fiscal year 2025
Net margin
8.6 %
fiscal year 2025
Average annual growth
+2.0 %
Revenue growth over 5 years
Average annual growth
-3.7 %
Revenue growth over 10 years
Market cap
2.4 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
20201.7 bn-796 m-45.9 %n/a
20211.9 bn131 m6.8 %+10.2 %
20222.0 bn66.3 m3.4 %+3.2 %
20232.0 bn-60.4 m-3.0 %+1.1 %
20242.0 bn-99.1 m-4.9 %+0.9 %
20251.9 bn165 m8.6 %-4.9 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Pediatrix Medical Group, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
2.48
gray zone (1.81 to 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
23.73 USD
DCF below share price · share price 31.45 USD, gap -24.6 %
Net Debt / EBITDA
1.20 x
moderate debt
Fiscal year20212022202320242025
Cash and investments487 m103 m178 m349 m500 m
Total Debt1.1 bn717 m702 m662 m660 m
Net Debt678 m707 m628 m432 m285 m
Equity896 m892 m849 m765 m866 m
Total assets2.7 bn2.3 bn2.2 bn2.2 bn2.2 bn
Operating cash flow76.7 m167 m137 m207 m271 m
Investments (capex)32.2 m29.7 m33.3 m22.0 m18.5 m
Free cash-flow44.5 m137 m104 m185 m253 m
Share buybacks4.7 m88.5 m919,0001.7 m86.7 m
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)16.79 x
Price / book value2.86 x
Return on Equity (ROE)17.3 %
Return on Invested Capital (ROIC)9.2 %
Net margin7.7 %
Debt / equity0.72 x
Current ratio1.28 x
Interest coverage6.71 x
Free cash-flow yield8.6 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

Pediatrix Medical Group, Inc. compared with its sector on the same exchange and with its main competitors.

Company P/E
14.0
49.6 % below the sector
Sector median P/E
27.7
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Pediatrix Medical Group, Inc.2.4 bn14.08.6 %
National HealthCare Corporation NHC3.3 bn26.47.9 %
Acadia Healthcare Company, Inc. ACHC3.5 bn19.0-33.3 %
Astrana Health, Inc. ASTH1.6 bn38.30.7 %
Aveanna Healthcare Holdings Inc. AVAH2.5 bn16.99.2 %
Ardent Health Partners, LLC ARDT2.5 bn14.32.1 %
LifeStance Health Group, Inc. LFST5.4 bn106.00.7 %
Guardian Pharmacy Services, Inc. GRDN3.1 bn43.43.4 %
Addus HomeCare Corporation ADUS2.3 bn18.46.7 %
Sector median (NYSE)27.7

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Pediatrix Medical Group, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
hold
33 analysts

Breakdown of ratings

strong buy 0buy 13hold 17sell 3strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 10 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Pediatrix Medical Group, Inc.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
29/10/20260.720.65+10.8 %
04/08/20260.630.59+6.6 %
05/05/20260.440.37+18.9 %
19/02/20260.500.53-5.7 %
03/11/20250.670.46+45.7 %
05/08/20250.530.42+26.2 %

Stock splits

DateOperation
20/12/2013split: 2 shares for 1
28/04/2006split: 2 shares for 1
01/03/1999split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 15/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Pediatrix Medical Group, Inc.

Free float
98.4 %
share of freely traded shares
Large funds tracked
20
hold the stock as of 2026Q2

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
BlackRock13.7 m347 m0.0 %+1.0 %2026Q2
Vanguard Group10.7 m229 m0.0 %-1.5 %2025Q4
State Street7.1 m179 m0.0 %+109.2 %2026Q2
Geode Capital Management2.2 m56.4 m0.0 %+1.7 %2026Q2
D. E. Shaw & Co1.6 m40.9 m0.0 %-5.6 %2026Q2
Morgan Stanley1.3 m33.7 m0.0 %+6.2 %2026Q2
Renaissance Technologies1.3 m32.6 m0.1 %-16.0 %2026Q2
Invesco1.2 m29.7 m0.0 %+27.3 %2026Q2

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 16/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 20/09/1995
ISIN code
US58502B1061
Workforce
4,120
full-time employees
Chief executive
Mark S. Ordan

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Pediatrix Medical Group, Inc.

What is the Pediatrix Medical Group, Inc. share price?

Latest recorded price: 31.30 USD on 13/11/2026, for a market cap of 2.4 bn USD.

What is the revenue of Pediatrix Medical Group, Inc.?

1.9 bn USD for fiscal year 2025, with net income of 165 m USD (net margin 8.6 %).

What do analysts say about Pediatrix Medical Group, Inc.?

Out of 33 analysts: 13 buy or strong buy, 17 hold, 3 sell or strong sell.

What is the P/E ratio of Pediatrix Medical Group, Inc.?

Trailing 12-month P/E of 14.0, against 27.7 for the sector median on the same exchange (10-year median: 22.3).

Is Pediatrix Medical Group, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US58502B1061).

How many employees does Pediatrix Medical Group, Inc. have?

4,120 full-time employees according to the latest published profile.

Who runs Pediatrix Medical Group, Inc.?

Mark S. Ordan is the company's chief executive.

Which large funds own Pediatrix Medical Group, Inc.?

As of 2026Q2, among the large funds tracked: BlackRock, Vanguard Group, State Street, Geode Capital Management, D. E. Shaw & Co.

07

Similar stocks